Compare Quest Diagnostics Inc (DGX) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Global X Lithium & Battery Tech ETF — how do they compare? Quest Diagnostics Inc trades at $230.9 (market cap $25.48B), while Global X Lithium & Battery Tech ETF trades at $69.5 (market cap $1.45B). The key difference: Quest Diagnostics Inc is far larger — about 17.6× Global X Lithium & Battery Tech ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Global X Lithium & Battery Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Global X Lithium & Battery Tech ETF for 56 Days on average.
| DGX | LIT | |
|---|---|---|
Market Cap | $25.48B | $1.45B |
Volume | 941,866 | 89,392 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $247.45 | $91.62 |
52-Week Low | $173.49 | $53.92 |
Typical Hold Time | 56 Days | 56 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.
The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.
LIT (Global X Lithium & Battery Tech ETF) trades at $69.51, down 2.2% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. Recent news highlights significant short interest decline (53.1% drop in September 2026) and positive catalysts from EV adoption trends. The ETF's performance reflects ongoing volatility in lithium markets amid shifting commodity prices and global electrification policies.
Outlook remains driven by long-term EV growth, though near-term risks include lithium price volatility and geopolitical tensions. Investment opportunity lies in exposure to battery technology leaders, balanced by sector-specific supply chain and regulatory uncertainties that could impact shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
